Recruitment

Recruitment Status
Completed

Summary

Conditions
Multiple Sclerosis
Type
Interventional
Phase
Phase 1
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Basic Science

Participation Requirements

Age
Between 18 years and 45 years
Gender
Both males and females

Description

Screening: 2 to 21 days before inclusion (Day -21 to Day -2) Institutionalization period: 6 days including 1 treatment day (Day -1 to Day 6, treatment on Day 1) Follow-up: 7-10 days (may be extended) End of study: Day 38 to Day 41 (may be extended) Total study duration: maximum 9 weeks

Screening: 2 to 21 days before inclusion (Day -21 to Day -2) Institutionalization period: 6 days including 1 treatment day (Day -1 to Day 6, treatment on Day 1) Follow-up: 7-10 days (may be extended) End of study: Day 38 to Day 41 (may be extended) Total study duration: maximum 9 weeks

Locations

Shanghai, 200025
Shanghai, 200025

Tracking Information

NCT #
NCT02046629
Collaborators
Not Provided
Investigators
Study Director: Clinical Sciences & Operations Sanofi